• Profile

Outcomes in men with metastatic castration-resistant prostate cancer who received sipuleucel-T and no immediate subsequent therapy: Experience at Dana Farber and in the PROCEED Registry

Prostate Cancer & Prostatic Diseases Feb 12, 2022

In this study, two datasets were used to analyze metastatic castration-resistant prostate cancer (mCRPC) patients managed with sipuleucel-T who did not immediately start subsequent therapy. Findings revealed delayed PSA response in a subset of patients suggesting delayed clinical activity.

  • Sipuleucel-T has shown survival advantage in phase 3 trials but is employed in few men with mCRPC partially because of low rates of PSA and objective response.

  • Among 1902 men who underwent treatment for mCRPC in PROCEED (an FDA-requested outcomes registry) and 255 patients treated consecutively with sipuleucel-T at Dana-Farber Cancer Institute (DFCI), 171 and 28 patients were included, respectively.

  • All patients exhibited increasing PSA before initiating sipuleucel-T and available post-treatment PSA measurements.

  • Clinical results of interest were: PSA <sub>50</sub> response rate, time to subsequent mCRPC directed therapy, and overall survival (OS).

  • In the PROCEED cohort, 19.9% demonstrated PSA <sub>50</sub> response at a median of 5.5 months (IQR: 3.9–9.5) since the last sipuleucel-T infusion; median time to subsequent mCRPC directed therapy and median OS were 10 months (95% CI: 9–11) and 49 months (95% CI: 43–NR), respectively.

  • In the DFCI cohort, 14.3% demonstrated PSA <sub>50</sub> response at a median of 6.3 months (IQR: 4.7–7.0); median time to subsequent mCRPC directed therapy and median OS were 9 months (95% CI: 9–11) and 60 months (95% CI: 51–74), respectively.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
M3 app logo
Choose easy access to M3 India from your mobile!

M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen